Navigation Links
VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
Date:11/4/2009

al results to differ materially from current expectations include, but are not limited to:

  • our ability to comply with the NASDAQ rules for continued listing in order to maintain the listing of our common stock on NASDAQ;
  • our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan from Bay City Capital by the December 31, 2009 maturity date (or earlier if certain repayment acceleration provisions are triggered);
  • our ability to control our operating expenses;
  • our ability to comply with covenants included in the loan from Bay City Capital;
  • our ability to timely recruit and enroll patients in any future clinical trials;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;
  • the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;
  • our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;
  • our ability to successfully commercialize VIA-2291;
  • our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;
  • our ability to obtain and protect our intellectual prope
    '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets
2. Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
3. Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
4. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
5. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
6. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
9. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
10. Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
11. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Today, Wall Street Reports announced ... GILD ), Health Management Associates Inc. (NYSE: HMA ... Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius Therapeutics ... of charge - including full price targets, industry analysis and ... Sciences, Inc. Research Report On June 7, 2013, ...
(Date:6/18/2013)... And EMERYVILLE, Calif. ... Inc. presented final results today from a Phase ... release) capsules demonstrating a statistically significant improvement in ... baseline at week 8 versus placebo in the ... investigational extended-release formulation of amantadine intended for once-nightly ...
(Date:6/18/2013)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... general corporate update in conjunction with its 2013 Annual Meeting ... 2:10 p.m. Pacific Time in Carlsbad, CA. ... follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders ... 2:10 p.m. – 3:15 p.m. Corporate Presentation – Stanley ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... cells have a much different and more complex ... University of Texas at Dallas have found that exploiting ... lung cancer. , In an article published online May ... Dallas researchers compared the metabolic characteristics of non-small-cell lung ... same patient. , They found that the cancer ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages 13 ... for Disease Control and Prevention (CDC). Of those, nearly 20 ... HIV Testing Day on June 27, Allsup, a nationwide provider ... CDC and other organizations are raising awareness of the importance ... new HIV infections each year. Along with developing AIDS, those ...
Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3
... , , , ... Sterling Communications Inc. , an independent, full-service, high-tech ... Knome to its client portfolio of industry-leading technology ... Knome has turned to Sterling to create a communications strategy ...
... , , , OCEANSIDE, N.Y., ... DEKAYE Consulting, Inc., announced the publication of his newest article, ... in the June 30, 2009 and July 14, 2009 issues of ... 12-13 and 12-14). Mr. DeKaye serves on the publication,s editorial ...
... Aug. 3, 2009 The new anti-wrinkle facial filler Dysport, ... reduced frown lines between the eyes, according to users and ... Southwestern Medical Center. "Our study confirmed that Dysport (abobotulinumtoxinA) ... Dr. Rod Rohrich, chairman of plastic surgery at UT Southwestern ...
... study finding suggests insulin treatment could boost the risk ... of the most widely used diabetes drugs, may offer ... pancreatic cancer by 60 percent, a new study shows. ... treatments, including the use of insulin or insulin-releasing medications ...
... , , LAS VEGAS, ... that expressdelivery.biz is a trusted merchant and its ability to honor ... have been verified by buySAFE. This certificate from the all-bonded online ... reliable and smooth online purchases with bond guarantees of up to ...
... , , CHICAGO, July 30 ... the leading global provider of risk management ... and Beverage Industry Report . The first annual report was ... remain abreast of emerging issues and learn how peers and competitors ...
Cached Medicine News:Health News:Knome Selects Sterling Communications as Agency of Record 2Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 2Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 3Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 4Health News:Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:US Discount Online Pharmacy Expressdelivery.biz Can Guarantee Safe and Enjoyable Shopping Experience With buySAFE Certificate 2Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 2Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 3Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 4
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
Inquire...
... 10.1 kg, Interior Dimensions (WxDxH): 31.1 x ... (WxDxH): 44.6 x 22.4 x 20.5 cm, ... 2 - 300 x 35 mm bottles, ... or 1 - 240 x 80 mm ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
Medicine Products: